Back to search

Aristotle University Of Thessaloniki (AUTH)

Άσθμα από ασπιρίνη και άλλα μη στεροειδή αντιφλεγμονώδη

Abstract

dc:description

Introduction: Bronchial asthma is a chronic inflammatory disease of the airways in which various types of cells like eosinophils, lymphocytes, mast cells, neutrophils and dendritic cells take part. Asthma is manifested with increased hyperresponsiveness of the airways promoting airflow limitation which is usually reversible either spontaneously or with proper medications. Aspirin and several others Non Steroid Anti-inflammatory Drugs (NSAIDs) induce further inflammation of respiratory tract in some asthmatic patients through a complex pathophysiological mechanism which includes COX-1 inhibition, overproduction of leukotrienes and genetic variations in the expression of inflammatory mediators. Aim: The main purpose of this study is to investigate the variations of exhaled Nitric Oxide (FeNO) in patients with Aspirin Exacerbated Respiratory Disease (AERD), during oral challenge procedures with three categories of NSAIDs: Aspirin (a COX-1 and COX-2 inhibitor), Nimesulide (a partially selective COX-2 inhibitor) and celecoxib (a selective COX-2 inhibitor). Secondary objective of this study is to investigate the prevalence of NSAID intolerance in a sample of asthmatic population of Northern Greece. Methods: For the purpose of this study, 60 people were included, 40 women and 20 men with an average age ± SD of 54,2 ± 6,04 years. Three study groups were formed: group A, which included 15 healthy individuals, group B, which included 15 patients with bronchial asthma without a history of NSAID intolerance, and group C which included 30 patients with asthma and a medical history suggestive of AERD, with positive Oral Aspirin Challenge (OAC). All the participants in the study underwent evaluation of the inclusion and exclusion criteria during their first visit. A second visit followed 7-10 days later, in which oral challenge with placebo was performed. The next day all the participants were submitted to OAC. Patients with positive OAC remained under constant medical supervision for at least six hours after the end of challenge. Visit four took place 7-10 days later and the participants underwent oral challenge with a partially selective COX-2 inhibitor. During the last visit which took place 7-10 days later, the participants underwent oral challenge with a selective COX-2 inhibitor. During all the challenge procedures, measurements of FEV1 and FeNO were carried out before the start of every challenge and every 45 minutes afterwards. Results: Aspirin and NSAID intolerance was found to be present at 12,9% in a sample of 937 asthmatic patients, after a review of their electronically registered medical history data. OAC was positive in 30 of the 39 patients submitted to it (76,9%). FeNO during OAC was statistically significant only in patients with AERD, compared both to the other groups (p<0,001), as well as to administration of placebo (p<0,001). Oral challenge with nimesulide was positive in four patients with AERD (13,3%). Levels of FeNO during nimesulide challenge were statistically significant only in the patients of group C, compared both to the other groups (p<0,001). There was a statistically significant correlation between positive bronchial reaction and FeNO increase (χ² = 16,133, p<0,001 and with Fisher's exact test p<0,001. During the oral challenge with celecoxib, none of the participants experienced any symptoms. A very small (ΔΝΟ=2,36 ppb and ΔΝΟ%=9,87%) but statistically important p<0,05 increase in FeNO occurred in group C during this challenge. The differences of FeNO levels in similar time points of oral challenge in group C where statistically very important (p<0,001) between the three categories of NSAIDs used. CONCLUSION: Intolerance to NSAIDs in the asthmatic population of Northern Greece seems to be rather high (12,9%), while OAC in patients with medical history suggestive of AERD has a high sensitivity (76,9%). During every oral challenge with NSAIDs, FeNO levels increased only in patients with AERD. The difference in the final FeNO increase between the three categories of NSAIDs used, reflects the varying potency of those categories in promoting inflammatory response in AERD patients, and establishes the greater safety of using selective COX-2 inhibitors in these patients. The increasing availability of FeNO-measuring devices in clinical practice, and the fact that FeNO measurement is a non-invasive, easy, fast and relatively inexpensive test, leaves room for further studies in order to further clarify the role of FeNO in diagnosis and management of patients with possible or confirmed AERD.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Ganavias, Lambros
  • Γκαναβίας, Λάμπρος

Subjects

dc:subject × 18

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/31581

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Ganavias, Lambros; Γκαναβίας, Λάμπρος. Άσθμα από ασπιρίνη και άλλα μη στεροειδή αντιφλεγμονώδη. Aristotle University Of Thessaloniki (AUTH), 2011. http://hdl.handle.net/10442/hedi/31581